Axsome Therapeutics, Inc. Q2 FY26 Earnings Analysis

- AUVELITY peak sales updated to at least $8 billion annually, with roughly equal contributions from Major Depressive Disorder (MDD) and Alzheimer’s disease (AD) agitation indications. - Continued growth expected for AUVELITY driven by expanded sales force (~630 reps) targeting 68,000 HCPs across multiple specialties and care settings. - Anticipated strong uptake from ongoing awareness campaigns, improved payer coverage (86% total coverage), and early frontline prescribing shifts. - SUNOSI revenue growing steadily, with 16% year-over-year growth in Q1 2026 and stable payer coverage (~83%). - SYMBRAVO showing 36% growth compared to Q4 2025, with sales force expansion and increasing primary care use. - Overall, revenue growth anticipated to continue, with operating leverage improving as top-line revenue outpaces operating expense growth. - Cautious near-term forecasting on Alzheimer’s Disease Agitation (ADA) uptake, but belief in transitory Q1 seasonality and robust longer-term ramp.

- Focus currently remains on revenue growth as the top priority. - Next goals after revenue growth are achieving cash flow positivity, followed by profitability. - Operating leverage expected as top-line revenue growth is anticipated to outpace operating expenses. - SG&A expenses likely to increase in Q2 2026 but at a slower rate, then level out. - Peak sales guidance: AUVELITY at least $8 billion, SUNOSI $300-$500 million, SYMBRAVO $500 million to $1 billion. - Expansion in sales force and market access expected to support continued strong revenue growth. - AUVELITY’s approval in two indications provides a clear line of sight to significant market potential. - IRA negotiations potentially impacting AUVELITY from 2031 onwards; current $8 billion peak estimate accounts for this. - Profitability is a mid-term goal, following revenue growth and cash flow positivity.

- No specific details on current or future capital expenditures (capex) or strategic investments are explicitly mentioned in the document. - The company is primarily focused on commercial execution, including expanding their sales force and marketing activities (e.g., AUVELITY and SYMBRAVO launches). - Investment efforts appear directed towards clinical development with several Phase III trials planned or ongoing (e.g., AXS-12, AXS-05, Solriamfetol programs, AXS-20 in late-stage development). - Acquisition history noted (e.g., SUNOSI acquisition), but current focus remains on pipeline and commercialization rather than new acquisitions. - Expansion of commercial infrastructure includes increased sales teams for SYMBRAVO and AUVELITY, indicating operational investments. - Cash balance of $305 million expected to fund operations through to cash flow positivity, suggesting no major unannounced capital projects at this time.

- The provided document (pages 4-15) does not mention any current or planned fundraising activities through debt or equity. - The focus is on commercial execution, product launches (AUVELITY in Alzheimer’s agitation), pipeline progress, and business development. - Financial discussions highlight revenue growth, operating leverage, and managing SG&A expenses but do not reveal plans for raising capital. - Past acquisitions (e.g., SUNOSI) are referenced but no new fundraising strategies are detailed. - Long-term financial goals include achieving cash flow positivity and profitability, indicating attention to financial discipline rather than immediate capital raises.

The document does not explicitly mention current, expected orderbook, or pending orders. However, related commercial progress and expectations include: - AUVELITY sales and launch efforts ongoing for Major Depressive Disorder (MDD) and new Alzheimer’s Disease Agitation (ADA) indication. - Expanded sales force calling on approximately 68,000 healthcare providers, targeting both MDD and ADA patients. - Strong growth in new patient starts and prescription activations expected to continue. - SYMBRAVO sales team expanded by 50 reps, payer coverage for 17 million lives secured. - SUNOSI maintains approximately 83% payer coverage, with 54,000 prescriptions written in Q1 2026 (16% YoY growth). - Preparations underway for ADA launch with final sales and marketing resources being finalized. - Anticipated incremental growth from ADA launch with uncertain but optimistic uptake over next 2-3 years. No specific numeric orderbook or pending order details disclosed.